Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients

Li Yu; Tian Ying; Yang XiaoMei; Cao NingJia; Li Zhu; Zhang Hong; Zhang XianJiao

doi:10.3969/j.issn.1001-5256.2018.05.017

Issue 5

May 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(5): 1011-1014

PDF( 1665 KB)

Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients

DOI: 10.3969/j.issn.1001-5256.2018.05.017

Department of Infectious Diseases, Shaanxi Provincial People's Hospital

Research funding:

Received Date: 2018-01-29
Published Date: 2018-05-20

Abstract

Abstract

Objective To investigate the effect of thymosin α1 therapy on the function of CD4+CD25+CD127dim/-regulatory T ( Treg) cells in chronic hepatitis B ( CHB) patients. Methods A total of 67 CHB patients who were admitted to Department of Infectious Diseases in Shaanxi Provincial People's Hospital from December 2016 to July 2017 were enrolled, among whom 38 patients received entecavir antiviral therapy ( control group) and 29 received entecavir combined with thymosin α1 for injection ( treatment group) . Peripheral blood mononucleated cells were isolated before and after treatment, and flow cytometry was used to measure the percentage of CD4+CD25+CD127dim/-Treg cells. CD4+CD25+CD127dim/-Treg cells were purified and co-cultured with autologous CD4+CD25-T cells. CCK-8 assay was used to measure cell proliferation, and ELISA was used to measure the levels of cytokines. The t-test was used for comparison of related indices between the two groups, the chi-square test was used for comparison of categorical data. Results In the control group, the percentage of CD4+CD25+CD127dim/-Treg cells was significantly reduced from 12. 32% ± 1. 22% at baseline to 8. 85% ± 2. 18% after 12 weeks of treatment ( t = 4. 579, P = 0. 0005) , while in the treatment group, this value was significantly reduced from 13. 71% ± 2. 32% at baseline to 9.26% ± 2. 30% after 12 weeks of treatment ( t = 4. 803, P = 0. 0003) . The measurement of cytokines was performed for 17 patients in the control group and 21 in the treatment group. After 12 weeks of treatment, the control group showed no significant changes in cell proliferation and levels of cytokines in the co-culture system of Treg and CD4+CD25-T cells; the treatment group had a significant increase in cell count in the co-culture system [ ( 3. 66 ± 0. 95) × 106 vs ( 2. 07 ± 0. 51) × 106, t = 5. 709, P < 0. 0001], as well as significant reductions in the levels of inhibitory cytokines interleukin-10 ( 41. 40 ± 11. 89 pg/ml vs 56. 53 ± 27. 85 pg/ml, t = 2. 639, P = 0. 019) and interleukin-35 ( 122. 9 ± 9. 98 pg/ml vs 130. 0 ± 15. 98 pg/ml, t = 2. 459, P = 0. 028) and significant increases in the levels of antiviral cytokines interferon-α ( 297. 5 ± 83. 56 pg/ml vs 235. 6 ± 67. 72 pg/ml, t = 2. 603, P = 0. 017) and interferon-γ ( 5. 83 ± 0. 85 pg/ml vs 4. 39 ± 0. 95 pg/ml, t = 4. 659, P = 0. 0004) . Conclusion Thymosin α1 can inhibit the level and immunosuppressive function of CD4+CD25+CD127dim/-Treg cells in CHB patients and improve their immune function.
- hepatitis B, chronic,
- T-lymphocytes, regulatory,
- thymosin

FullText(HTML)

References(17)

References

[1]WU FP, DANG SS.Research advances in immune tolerance in chronic hepatitis B virus infection[J].J Clin Hepatol, 2017, 33 (5) :949-953. (in Chinese) 吴凤萍, 党双锁.慢性HBV感染免疫耐受研究进展[J].临床肝胆病杂志, 2017, 33 (5) :949-953.

[2]SASIDHARAN NAIR V, ELKORD E.Immune checkpoint inhibitors in cancer therapy:a focus on T-regulatory cells[J].Immunol Cell Biol, 2018, 96 (1) :21-33.

[3]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[4]ZHANG Y, LIAN JQ, HUANG CX, et al.Overexpression of Tolllike receptor 2/4 on monocytes modulates the activities of CD4 (+) CD25 (+) regulatory T cells in chronic hepatitis B virus infection[J].Virology, 2010, 397 (1) :34-42.

[5]LI X, TIAN L, DONG Y, et al.IL-35 inhibits HBV antigenspecific IFN-γ-producing CTLs in vitro[J].Clin Sci, 2015, 129 (5) :395-404.

[6]SHAO X, MA J, JIA S, et al.Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection[J].Front Cell Infect Microbiol, 2017, 7:472.

[7]TIAN ZF, YOU ZL, YI H, et al.Effect of entecavir on CD4+Tcell subpopulations in patients with chronic hepatitis B[J].Ann Hepatol, 2016, 15 (2) :174-182.

[8]HAO C, WANG J, KANG W, et al.Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B[J].Viral Immunol, 2013, 26 (5) :336-342.

[9]CHEN T, ZHU L, SHI A, et al.Functional restoration of CD56 (bright) NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B[J].Hepatol Int, 2017, 11 (5) :419-428.

[10]PAN Y, WANG LN, SONG ZX, et al.Comparison of effects of entecavir and interferon therapy for HBe Ag-positive chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (4) :382-395. (in Chinese) 潘玉, 王莉娜, 宋正霞, 等.恩替卡韦与干扰素治疗HBe Ag阳性慢性乙型肝炎的疗效[J/CD].中华实验和临床感染病杂志:电子版, 2016, 10 (4) :392-395.

[11]ZHANG HQ, LIU H, ZHOU T.Clinical effect of adefovir dipivoxil combined with thymosinα1 in the treatment of paitents with HBe Ag positive and no response to lamivudine[J].Int J Virol, 2016, 23 (2) :124-126. (in Chinese) 张华强, 刘海, 周涛.阿德福韦酯联合胸腺肽α1治疗拉米夫定无应答的HBe Ag阳性慢性乙肝的疗效观察[J].国际病毒学杂志, 2016, 23 (2) :124-126.

[12]HE C, PENG W, LI C, et al.Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection[J].Medicine, 2017, 96 (16) :e6606.

[13]TONG J, SUN CY, YANG LB, et al.Effect of thymosinα1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis[J].J Clin Hepatol, 2017, 33 (11) :2132-2135. (in Chinese) 仝静, 孙长宇, 杨黎冰, 等.胸腺肽α1对乙型肝炎肝硬化失代偿期患者淋巴细胞亚群的影响[J].临床肝胆病杂志, 2017, 33 (11) :2132-2135.

[14]DING JH, WANG LL, CHEN Z, et al.The role of Tα1 on the infective patients after hematopoietic stem cell transplantation[J].Int J Hematol, 2013, 97 (2) :280-283.

[15]GARIB FY, RIZOPULU AP.T-regulatory cells as part of strategy of immune evasion by pathogens[J].Biochemistry, 2015, 80 (8) :957-971.

[16]CHEN X, DU Y, LIN X, et al.CD4+CD25+regulatory T cells in tumor immunity[J].Int Immunopharmacol, 2016, 34:244-249.

[17]LIN FC, YOUNG HA.Interferons:success in anti-viral immunotherapy[J].Cytokine Growth Factor Rev, 2014, 25 (4) :369-376.

Relative Articles

[1]	Xue Miao, Mao XiaoRong, Chen Hong. Change in T helper 17 cell/regulatory T cell imbalance in rats with immunological liver injury[J]. Journal of Clinical Hepatology, 2020, 36(1): 149-152. doi: 10.3969/j.issn.1001-5256.2020.01.033
[2]	Wang HaiYan, Zhu Li, Wang YinLing, Zhu YuePing, Zhu XiaoYan, Chai XiaoZhe, Qian Feng, Li Ming, Zhu ChuanWu. Impact of pegylated interferon versus conventional interferon on the change in peripheral CD4+CD25highT cells in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(1): 53-57. doi: 10.3969/j.issn.1001-5256.2018.01.011
[3]	Chen Bin, Zhang Tao, Zhu WenFang, Peng Jie, Zhang QianQian, Li YunFang, Ding XiuLi. Effect of the warming and heat-clearing method on the percentage of regulatory T lymphocytes/T helper 17 cells in rats with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2018, 34(12): 2642-2647. doi: 10.3969/j.issn.1001-5256.2018.12.026
[4]	Gao WeiHua, Ge KuanXue, Xiang XiaoXing. Association of Th17 cells, regulatory T cells, and their imbalance with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(6): 1347-1350. doi: 10.3969/j.issn.1001-5256.2018.06.046
[5]	Ge KuanXue, Gao WeiHua, Xiang XiaoXing. Association of regulatory T cells, T helper 17 cells, and change in their balance with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1573-1576. doi: 10.3969/j.issn.1001-5256.2018.07.045
[6]	Tong Jing, Sun ZhangYu, Yang LiBing, Liang YaLin, Kang YanNan. Effect of thymosin α1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2132-2135. doi: 10.3969/j.issn.1001-5256.2017.11.016
[7]	Guo FeiBo, Wu JunZhu, Ai LiMing, Song Ying. Clinical significance of Th17/Treg and associated cytokines in peripheral blood in chronic hepatitis C patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 479-484. doi: 10.3969/j.issn.1001-5256.2017.03.017
[8]	Guo FeiBo. Change in peripheral blood CD4~+ regulatory T cells and its association with antiviral effect in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(12): 2317-2321. doi: 10.3969/j.issn.1001-5256.2016.12.017
[9]	Zhou Yan, Jing Xiang, Zhu ZhengYan. Roles of regulatory T cells and T-helper cells in hepatitis B virus-related liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(10): 1994-1997. doi: 10.3969/j.issn.1001-5256.2016.10.040
[10]	He JunNan, Zhao ShouSong. Research advances in association between regulatory T cells and hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2016, 32(2): 361-365. doi: 10.3969/j.issn.1001-5256.2016.02.036
[11]	Li CaiDong, Chen XiLian, Tian PengFei, Li HuiJun, Wu Bin. Correlation analysis of percentages of T lymphocyte subsets and CD4~+CD25~+ regulatory T cells and HBV DNA level in peripheral blood of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2015, 31(4): 541-545. doi: 10.3969/j.issn.1001-5256.2015.04.016
[12]	Cheng Ping, Xue BoYu. Research progress in Treg/Th17 imbalance in persistent HBV infection[J]. Journal of Clinical Hepatology, 2015, 31(4): 603-606. doi: 10.3969/j.issn.1001-5256.2015.04.031
[13]	Zhou LengXiao, Han Tao, Xing Jing, Lu Xu. Role of thymosin β4 in liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(12): 2100-2103. doi: 10.3969/j.issn.1001-5256.2015.12.027
[14]	Huang JinFa, Xu Tao, Pan XingNan, Lai XiaoHuan, Zheng LianQiu, Huang ZhiJie. Measurement of peripheral blood Treg,Tr1,and Th17 cells in patients with chronic hepatitis B and its clinical significance[J]. Journal of Clinical Hepatology, 2015, 31(4): 551-555. doi: 10.3969/j.issn.1001-5256.2015.04.018
[15]	Qi YouTao, Zuo WeiZe. Efficacy of lamivudine and thymosin alpha-1 combination therapy in treatment of HBeAg-positive chronic hepatitis B: a meta-analysis[J]. Journal of Clinical Hepatology, 2014, 30(7): 639-643. doi: 10.3969/j.issn.1001-5256.2014.07.016
[16]	Lu JianGuo. Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(12): 922-925. doi: 10.3969/j.issn.1001-5256.2013.12.012
[17]	Chen HuiJuan, Zhao ShouSong. Recent insights into the roles of regulatory T cells in viral hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(11): 868-871.
[18]	Wu YinYa, Tan ShanZhong, Zhao Lei, Sun WeiWei, Shen JianJun, Liang ZhongFeng. The changes and value of the proportion of CD4+CD25+ regulatory T cells in HBeAg (+) and HBeAg (-) ASC in peripheral blood[J]. Journal of Clinical Hepatology, 2012, 28(3): 209-211.
[19]	Jiang ShuLian, Tan ShanZhong, Wen Jian. Role of CD4+CD25+ T regulatory cells in HBeAg seroconversion during interferon antiviral[J]. Journal of Clinical Hepatology, 2012, 28(7): 528-530.
[20]	Xing Jing, Han Tao, Zhu ZhengYan, Liu Ying, Liu Hua, Guo Zhen, Ma XiaoYan, Pei YanZhen. Serum thymosin β4 level in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(4): 387-390.

Supplements(0)

Cited By

Cited by

Periodical cited type(16)

1.	倪友琼，胡乃毅，张紫涵. 柴胡三石解毒汤加味对慢性肝炎的治疗效果及对患者COX-2、CD127表达的影响. 四川中医. 2024(04): 114-117 .
2.	杨瑞海，王云鹏. 中药浸泡联合ALA-PDT治疗跖疣的疗效及对患者调节性T细胞、TGF-β、IFN-γ的影响. 中国美容医学. 2023(04): 111-114+122 .
3.	裴思颖，梁群，蔡国锋，贾坤平，王虹. 血必净联合胸腺肽对老年肺部感染合并脓毒症患者的免疫调节作用及对血清PCT、S-ChE的影响. 药物生物技术. 2023(02): 157-161 .
4.	陈闯嘉宝，黄秉洲，邓李霜，徐志文. 胸腺肽的免疫调节活性及其在病毒性疾病中的应用. 畜牧与兽医. 2023(11): 138-144 .
5.	陈业京，陆清平. 胸腺肽联合恩替卡韦治疗慢性乙型肝炎的疗效及对患者免疫功能的影响. 临床合理用药杂志. 2022(25): 104-106 .
6.	孙焱，景伟芳，薛莉. 5-氨基酮戊酸光动力疗法联合中药方剂治疗跖疣的效果及对外周血CD4~+CD25~+CD127~(dim/-)调节性T细胞的影响. 中国医药导报. 2021(07): 108-112 .
7.	严锡祥，郑爱东，张振恩，潘国翠，崔永华. 胸腺肽α1免疫治疗联合抗感染对重症肺部感染的影响. 中华肺部疾病杂志(电子版). 2021(03): 301-304 .
8.	何其瑞. 慢性乙型肝炎患者外周血CD45~+T淋巴细胞亚群评估患者病情的检测意义分析. 山西医药杂志. 2021(13): 2113-2115 .
9.	卢琼. 乙肝患者血清T淋巴细胞亚群水平与HBV-DNA载量的相关性. 西藏医药. 2021(04): 30-31 .
10.	熊芳，高耀，马艳品，于乐乐，谭炳琴，鲍旭丽，闾军. 干扰素α和胸腺五肽协同干预对HepG2.2.15细胞APOBEC3A和APOBEC3B mRNA表达的影响. 临床肝胆病杂志. 2020(01): 76-79 . 本站查看
11.	刘雪妮，刘春华，亓梅. 恩替卡韦+胸腺肽治疗乙型肝炎肝硬化的效果及不良反应观察. 中国医药科学. 2020(11): 62-65 .
12.	杜秀菊. 胸腺肽α_1对96例慢性肝病患者T细胞亚群影响的临床观察. 中国医药指南. 2019(08): 148-149 .
13.	张正华，金红弟，沈国辉，张月萍，张秀华. HBeAg阳性慢性乙型肝炎患者自发性HBV DNA滴度下降对恩替卡韦的疗效预测. 临床合理用药杂志. 2019(16): 79-81 .
14.	宛月. 人工肝配合胸腺肽α1在晚期肝衰竭患者免疫调节中的疗效分析. 广西医科大学学报. 2019(10): 1623-1626 .
15.	袁艺萌，王欣悦. 阿德福韦酯联合胸腺肽α1治疗慢性乙肝的效果探讨. 中国现代药物应用. 2019(24): 166-168 .
16.	胡仁标. 恩替卡韦治疗慢性乙型肝炎病毒感染临床效果观察. 临床合理用药杂志. 2019(35): 61-62 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2344) PDF downloads(396)

Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients

DOI: 10.3969/j.issn.1001-5256.2018.05.017